The medication is administered once weekly via subcutaneous injection, typically starting at 2.5 mg and gradually increasing by 2.5 mg every 4 weeks up to a maximum of 15 mg, to minimise gastrointestinal side effects
Medical conditions may include but are not limited to diabetes, hypothyroidism, gastroesophageal reflux disease (GERD), Barretts esophagus, dysphagia, esophagitis, cirrhosis, prior abdominal surgeries or procedures, gastric polyps, varying autoimmune diseases, pain disorders, psychiatric diseases, neuromuscular disorders, obstructive sleep apnea (OSA), or general ASA physical status classifications
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M
therefore, it can pose health risks to target consumers